Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. While target therapies have changed the outcomes of patients harboring actionable mutations, resistance inevitably emerges. Circulating tumor DNA (ctDNA) offers a minimally invasive tool for capturing tumor evolution in real time. This approach enables the rapid detection of resistance mechanisms, complements or substitutes for tissue re-biopsy, and reduces the burden of invasive procedures for patients. In this review, we summarize the current evidence on the use of liquid biopsy to uncover resistance mechanisms in patients progressing on targeted therapies, with a focus on its role in dynamic tumor profiling and longitudinal disease monitoring.
非小细胞肺癌（NSCLC）仍是全球癌症相关死亡的主要原因。尽管靶向治疗已显著改善携带可作用突变患者的预后，但耐药现象仍不可避免地出现。循环肿瘤DNA（ctDNA）作为一种微创检测工具，能够实时捕捉肿瘤的演化过程。该方法可快速识别耐药机制，补充或替代组织再活检，并减轻患者因侵入性操作带来的负担。本文综述了当前利用液体活检揭示靶向治疗进展期患者耐药机制的证据，重点探讨其在动态肿瘤谱分析及纵向疾病监测中的作用。
Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies
肿瘤(癌症)患者之家